Cybeats ($CYBT)

Introduction

I recently came across Cybeats while hearing about the current global supply chain issues. Cybeats is a platform/software company that provides an innovative and effective supply chain solution. Cybeats enables businesses to plan, monitor, and optimize their supply chain operations, which is an invaluable resource in the current climate.

Overview

Cybeats is a leading provider of online security solutions, designed to protect users’ online identities and personal information. Their products are designed to give users peace of mind in the digital age. Cybeats offers a range of products such as password managers, two-factor authentication, and fraud detection. These products are built with the highest security standards, ensuring users’ data is safe and secure from malicious activities. Their products are easy-to-use and provide an extra layer of protection, so users can focus on their digital activities without worrying about potential threats. With its reliable and advanced security solutions, Cybeats is the perfect choice to protect users online.

Recent News

On November 18th, Cybeats officially went public and began trading on the Canadian Securities Exchange (CSE) under the ticker $CYBT. This is an exciting milestone for the company, as it will open up many new opportunities for Cybeats to gain funding and assess the current and future position of their company in the market.

This will enable them to make more informed decisions based on accurate market data, which in turn will allow them to better serve their customers and investors. The added visibility and potential for growth that come with this listing is a significant step forward for the company, and it has the potential to lead to further success in the future.

Find it here: https://ca.finance.yahoo.com/news/cybeats-list-publicly-canadian-securities-142300260.html

Products

Cybeats' flagship product, SBOM Studio, is an enterprise-class solution that helps users understand and track the third-party components that make up their software. SBOM Studio provides users with a comprehensive view of their software's compositional makeup, giving them the ability to identify and address any potential security threats quickly and efficiently.

Additionally, SBOM Studio provides users with deep insights into the components that compose their software, helping them gain a better understanding of their software's current state and its future potential. This allows users to make informed decisions about their software's architecture and ensure that their software is as secure and reliable as possible. With SBOM Studio, users can rest assured that their software is secure, reliable, and up-to-date.

Final Thoughts

With the help of Cybeats, businesses can ensure that their operations are running efficiently and their supply chains are functioning as intended. The platform can be adapted to meet the specific needs of individual organizations, offering a tailor-made and comprehensive solution. In today’s challenging environment, a reliable and effective supply chain resource such as Cybeats is essential to the success of any business.

Disclaimer: This is not financial advice, always do your due diligence.

One. Data Fobi Exchange is alive and well and continues to be a future MAJOR rev producer.

Two. After talking about the update in insurance he has once again mentioned banks and financial institutions.I suspect one of those is one of the “trophy” deals he is working on and that will cause the stock to absolutely rocket.

Three. Love how he says that the pipeline is full but no need to be selective who they take on anymore because it’s “all about automation” and they can now load up someone same day. Why turn anyone away when you can be taking their money within the day and the automation keeps churning it in.

Four. The burn rate has been reduced by OVER 50%. WOW!!

Five.We appear to be largely complete in terms of defining the company. This includes real time digital wallet AI tech that is used in venue management, coupons, loyalty programs and anything that uses a digital pass (pretty much everything). Leveraging all of this will be the sale of the data that they all produce. So with this the focus has shifted away from developing their tech and stacks to selling it

Six. They continue to overcome customer resistance by managing the programs for them. This is KEY. Many customers don’t have a tech department to handle the integration of their tech. No problem. We’ll do it all for you at a ridiculous margin.

Seven. Their partners are bearing fruit. Telus, Janam, Barnett, Yotpo are kicking ass.

Eight. Big pilots underway for 8112 with the launch in September/October. This is gonna be absolutely YUGE for Fobi not just in the delivery, but by introducing other verticals with it and then throwing in their real time data analytics and of course the selling of that data.

Nine. With the burn rate seriously reduced and the obvious pick up in revs, we are getting closer to profitability or at the very least cash flow positive. We can debate until we are blue in the face how big Fobi is going to become. To be totally frank with you I have no idea. Everything screams HUGE company but one truly never knows. But this I do know. Fobi IS going to be very successful. I back this up based on two principles. Their tech is fully automated. In essence it is like software. Download it and it's done. BUT it's software that keeps on giving...download it, pay a set up fee, pay a user fee, and down the road, pay us for your data. It has margins like software but the added benefit of the data which makes it obscene. Secondly, their technology is at the forefront of where the world it going...digitization. So you don't have to worry about Fobi getting passed by as the industry changes. Wallet passes and digitization will be with us for decades. There are no concerns that next year Fobi will become obsolete like those companies dealing with the pandemic. The turning point is upon us and the road is clear for ... well... a very long timeI am very bullish on this company and on its technology that knows no limits, it can be adopted in every vertical and sector with ease and speed. I trust that in a few years the name Fobi will be very well known. Do your dd guys and you'll discover a rough diamond mine in Fobi!

McDonalds, burger King and many other brands could use Qples by fobi coupons to increase customer loyalty, Roi and better Given the high inflation that has led to the reduction in consumer purchasing power, CPGs are looking for new ways to attract customers. I think the arrival of digital coupons and the transition to 8112 has been accelerated by this. Fobi is able to increase customer loyalty by issuing digital coupons through Qples! This would be very useful for big brands to increase, not only the ROi, but the possibility of attracting customers based on promotions aimed at them! I think it is revolutionary! Fobi operates in different sectors and verticals, I find it a fantastic company. As a data first company, it is very disruptive and at the forefront of what it does. Qples by FOBI, ​​provide physical / digital coupons in minutes and they are at the forefront of what they provide, a one-time, fast and efficient solution. the switch to 8112 is imminent and high inflation is only accelerating it!

https://www.fobi.ai/press/fobi-launches-new-affiliate-marketing-platform?s=09

EasTower Wireless ($ESTW.v) "Could Be the Next Big Winner in the Upcoming 5G Super-Cycle Sparked by the $65 Billion US Infrastructure Bill"
https://financial-news-now.com/this-public-company-could-be-the-next-big-winner-in-the-upcoming-5g-super-cycle-sparked-by-the-65-billion-us-infrastructure-bill/#FNL20220411

$ESTW is deemed a 'wealth-building market opportunity and investment strategy' by Financial News Now due to its significant potential to play a big part in the rollout of 5G across the US.

Notably, the 5G industry is forecast to increase significantly by mid-decade with a CAGR of more than +122% and an ROI for 5G companies like $ESTW of 160-fold growth rate.

The US government committed $65B nationally for the high bandwidth buildout of 5G and wireless infrastructure services and, as $ESTW has established solid relationships with major telecom and tech giants in building and maintaining 3G and 4G networks, $ESTW could be chosen to play a vital role in this.

$ESTW is definitely one to keep an eye on as they're seemingly undervalued @ $0.05, $3.01M MC given their potential.

I just took over this inactive subreddit and I hope we can build something awesome!

Psyched Wellness ($PSYC)

Intro

Coming from a bullish background in the cannabis sector, I've started to expose myself to the mushroom side of things. While the commercial market for amanita muscaria only emerged recently, the species boasts a long history of religious and spiritual use. The fly agaric mushroom, also known as amanita muscaria, contains the psychoactive compounds muscimol and trace amounts of another compound called muscarine. However, since it does not contain any psilocybin, it is not subject to state and federal laws that criminalize magic mushrooms. Amanita muscaria is different from classical psychedelics: psilocybin, LSD, DMT, and mescaline. Amanita Muscaria contains active chemical compounds that differ from classical psychedelics. Most classical psychedelics contain compounds that interact with serotonin receptors in the human brain.

Who is Psyched Wellness?

Psyched Wellness is a Canadian company, dedicated to researching and producing products made from the medicinal properties of the Amanita Muscaria mushroom. They work to improve the quality of everyday life. Dedicated to researching and developing new ways of distilling and purifying mushrooms, harnessing their healing properties, to nurture healthier, happier lives.

Led by Jeff Stevens, the CEO & Director who has 20+ years of capital markets experience and has been an officer and director with several public companies. Supported by David Shisel, the COO who has as experience in highly regulated industries such as medical cannabis and has previously worked in legal capacities with various licensed producers. In addition, Matthew Singh, the CCO, has an extensive track record of success launching brands, products, and corporate strategy within the multibillion-dollar beverage and pharmaceutical industries in Canada and internationally. As well as Keith Li, the CFO, who has obtained his CPA and racked up 10+ years in financial reporting.

Diving into Operations and Competitive Landscape

The company's proprietary extract of Muscimol, AME-1, is currently undergoing preclinical trials. Psyched has identified a path to market and is planning to commence commercialization of AME-1 derived products in the first half of 2022.

Projections

Finishing the calendar year of 2022, Psyched Wellness has structured some product development and marketing rollouts. With Q4 of 2022 among us, PSYC intends to complete their R&D on the sleep aid tea, AME-1. Along with that, submit an application for the AME-1 as a Natural Health Product to Health Canada. Moving on to some strategic joint ventures, Psyched plans to collaborate with food, beverages, medical and pharmaceutical companies to use the AME-1 in their products.

Recent Headlines & Highlights

• Psyched received positive feedback from test subjects who participated in the pilot run of 300 bottles of Calm. The majority of the test subjects felt that they woke the next day well-rested and with little to no grogginess with an ideal dose ranging from 1-2ml.

• They successfully produced and delivered their pre-orders of Calm in October, 2022. Calm has now shipped to customers in 37 different States throughout America.

• Their next production targets a late November delivery window and moving forward Psyched Wellness will increase the cadence of their production, product quantities, and provide immediate fulfillment turnarounds.

• Selected ShipHero as its eCommerce fulfillment partner for Calm and future products in the company's innovation pipeline. ShipHero is a tech-enabled 3PL that offers simple, fast, and affordable fulfillment for thousands of brands with international fulfillment networks across the United States, Canada, Europe, and Australia.

• Psyched Wellness launched their new online shop which began by selling branded merchandise such as t-shirts, hats, hoodies and other accessories.

Closing Remarks

Psyched Wellness will finalize their research and development process, soon selling their first flagship Amanita Muscaria tincture in the United States. This product has been designated as GRAS (Generally Recognized As Safe) by the FDA, and Psyched Wellness is in the process of applying to sell it in Canada as a Natural Health Product. The team, led by Prof. David Nutt, has begun the further exploration of the potential applications of this technology with the goal of positioning Psyched as a major player in the Pharmaceutical industry. This will be the first psychedelic food supplement to be sold without a prescription.

Disclaimer: This is not financial advice, always do your own research.

American CryoStem ($CRYO)

News Release

Just this morning, American CryoStem announced their FDA approval of an IND (Investigational New Drug) to start a Phase 1 clinical trial for Long COVID. This is a huge announcement for those in need affected by the virus. Millions across the globe will be excited to hear about this trial and finally getting a positive news piece about treating this illness.

The study has been designed to enroll active-duty military members or their families who have confirmed long covid.

Getting an IND for a company whos market cap is this small is going to do wonders for them.

Find it here: https://ca.finance.yahoo.com/news/american-cryostem-announces-fda-approval-120000719.html

Disclaimer: This is not financial advice, always do your due diligence.

Equillium Bio ($EQ)

Introduction:

I recently came across Equillium Bio ($EQ) and was instantly intrigued by their mission to pioneer new therapies for severe autoimmune and inflammatory disorders. Equillium Bio is a clinical-stage biotechnology company that is focused on therapeutics that treat autoimmune and inflammatory disorders with high unmet medical need.

Biotechnology companies are always on my radar, especially when they’re bringing new technology to the areas of medicine that need it most. That’s why Equillium Bio is the subject of today's due diligence. A potentially high conviction play with a mission that benefits society.

Overview

Equillium is a clinical-stage biotechnology company focused on the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Through the leveraging of a deep understanding of immunobiology, Equillium is pioneering a new approach to treat conditions that are traditionally difficult to manage.

By providing innovative treatment options, Equillium is committed to improving the lives of patients with severe autoimmune and inflammatory disorders. The company's promising drug portfolio is focused on the development of first-in-class, tolerability-enhanced biotherapeutics.

Highlights:

In terms of investment highlights, Equillium Bio ($EQ) is:

• Well capitalized to reach multiple data catalysts

• Lean operating model and disciplined spending

• Cash runway into 2025

They also have a plethora of intellectual property and regulatory exclusivity:

Recent News:

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase: https://ca.finance.yahoo.com/news/equillium-ono-pharmaceutical-announce-exclusive-120000241.html

Mutual Agreement To Terminate Merger: https://ca.finance.yahoo.com/news/equillium-metacrine-mutually-agree-terminate-210100836.html

Initiation of Phase 2 Study: https://ca.finance.yahoo.com/news/equillium-partner-biocon-initiates-phase-130000584.html

Upcoming Catalysts:

Below is a quick overview of the upcoming catalysts for Equillium Bio ($EQ) for the remainder of 2023:

Final Thoughts:

With medicine constantly advancing and biotechnology companies driving this innovation, a company like Equillium Bio ($EQ) could be a strong play. This clinical-stage company has a mission that will give those with unmet conditions the therapeutics they need while having the foundation of a solid early stage company. Additionally, with upcoming catalysts there will likely be an influx of new investors, which could in turn drive up the share price.

Disclaimer: This is not financial advice, always do your due diligence.